---
schema_version: "secwatch.filing_event.v1"
accession: "0001000694-23-000050"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T00:09:58.150298+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Novavax Q2 net income $58M on $424M revenue; SK bio partnership & Canada APA strengthen finances

## Summary
- Q2 total revenue $424M (up from $186M); net income $58M vs net loss $510M in Q2 2022.
- Updated FY 2023 revenue guidance to $1.3B-1.5B (from $1.4B-1.6B); combined R&D/SG&A cut to $313M from $398M.
- SK bioscience $85M equity investment at $13/share (59% premium); $195M manufacturing liability settled for $154M.
- Initiated FDA submission for updated XBB COVID vaccine; expect availability by September 2023.
- Reduced current liabilities by $864M in H1 2023; total reduction over $1B including SK bioscience deal.

## SEC filing metadata
- accession: 0001000694-23-000050
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000100069423000050/0001000694-23-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000100069423000050/nvax-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001000694-23-000050
- JSON: https://secwatch.observer/filing/0001000694-23-000050.json
- Plain text: https://secwatch.observer/filing/0001000694-23-000050.txt

## Key facts
- Earnings Releases
  NOVAVAX INC reported Quarter Ended June 30, 2023 results: revenue $424 million, net income $58 million.
  - Period: Quarter Ended June 30, 2023
  - Revenue: $424 million
  - Net income: $58 million
  - Result: reported results
  source text: Novavax Reports Second Quarter 2023 Financial Results and Operational Highlights • Second quarter total revenue of $424 million and net income of $58 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1000694/000100069423000050/0001000694-23-000050-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.